Natera Presents Updated Analyses From ALTAIR Clinical Trial at ASCO GI
Study showed a statistically significant disease-free survival (DFS) benefit in all SignateraTM-positive patients following blinded central review AUSTIN, Texas–(BUSINESS WIRE)–Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that new data from the ALTAIR trial will be presented at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium … [Read more…]
